UCLA Scientists Develop Off-the-Shelf CAR-NKT Immunotherapy to Combat Aggressive and Recurring Endometrial Cancer

UCLA researchers develop a new off-the-shelf CAR-NKT cell therapy that eliminates aggressive endometrial tumors in models using a unique triple-attack pathway.

By: AXL Media

Published: Mar 17, 2026, 5:24 AM EDT

Source: Information for this report was sourced from UCLA Health Sciences

A Multi-Pronged Offensive Against Gynecologic Malignancies

Endometrial cancer remains a persistent challenge in the United States, distinguished as one of the few oncological fields where survival rates have declined over recent decades. While uterine papillary serous carcinoma represents only 10 percent of cases, it accounts for nearly 40 percent of total deaths, highlighting a desperate need for more effective interventions. To address this, researchers at UCLA Health Sciences have developed a CAR-NKT cell therapy that utilizes a rare type of immune cell known as invariant natural killer T cells. According to the study published in Experimental Hematology & Oncology, these cells are engineered to target mesothelin, a protein frequently overexpressed in aggressive endometrial cancer cells, providing a more robust defense than existing treatments.

The Triple-Threat Mechanism of NKT Cell Engineering

Traditional CAR-T therapies typically rely on a single recognition mechanism to identify and attack cancer, which often allows tumors to adapt and escape. In contrast, the UCLA-developed CAR-NKT cells are capable of detecting and destroying tumor cells through three simultaneous pathways. Dr. Lili Yang, a professor of microbiology and immunology at UCLA, explains that this triple-attack strategy prevents the cancer from evolving a defense quickly enough to survive. By hitting the malignancy from multiple biological angles at once, the therapy ensures that even highly adaptive aggressive subtypes are unable to find a safe harbor within the body.

Preclinical Success and Superior Survival Outcomes

The efficacy of this new immunotherapy was most evident during testing in mouse models, where it achieved complete tumor elimination and significantly prolonged survival. When compared to conventional CAR-T cells, which only offered temporary and partial control before the cancer returned, the CAR-NKT cells proved far more resilient and thorough. According to Dr. Sanaz Memarzadeh, a gynecologic oncologist at UCLA, these results were consistent across various patient-derived tumor cell lines. This superior killing ability suggests that the therapy could finally offer a solution for patients who have seen their cancer return after undergoing the standard regimen of surgery, chemotherapy, and radiation.